Itragerm Itraconazole, the broad-spectrum antifungal now in a new improved pharmaceutical form

Itragerm 50 mg is the first low-dose itraconazole on the market, and thanks to its SUBA drug administration technology, it improves the bioavailability of its soluble substances, increasing the drug’s absorption and reliability1.

1 capsule of Itragerm 50 mg is equivalent to one conventional Itraconazole 100 mg capsule

Active ingredient The first low-dose itraconazole on the market

Itragerm 50 mg is indicated for the treatment of superficial mycoses such as: dermatomycosis (e.g. tinea corporis, tinea cruris, tinea pedis and tinea manus) and pityriasis versicolor; and for the treatment of systemic mycoses such as: candidiasis, aspergillosis and histoplasmosis. The official recommendations concerning the appropriate use of antifungal agents should be taken into consideration.

Itragerm 50 mg

Soluble microparticles

Itraconazole 100 mg

Insoluble crystals

Itragerm 50 mg

Soluble microparticles

Itraconazole 100 mg

Insoluble crystals

More absorption Better plasma bioavailability than conventional Itraconazole

Thanks to SUBA technology, Itragerm 50 mg improves the plasma bioavailability of itraconazole by 80-90% versus 55% of the conventional formulation.

In Itragerm, absorption is not affected by the gastric pH, so patients who are taking proton-pump inhibitors can now continue to do so.

More reliability The right dose for your patients

Unlike the conventional formulation, Itragerm presents much less variability in terms of absorption both inter and intrapatient, with very stable areas under the curve irrespective of the conditions under which the drug is taken.

This means that the result of the treatment1 is highly predictable, preventing the dispersion factor associated with conventional Itraconazole between super- and sub-absorber patients. 1. Mudge S, Hayes D, Ellis D. Mayne Pharma International Pty Ltd, School of Molecular & Biomedical Science, University of Adelaide.

More convenience Easy to administer, easy to take

With Itragerm, patients are not subject to meal times, as it can even be administered on an empty stomach. Also, as it is a smaller capsule, it is easier to swallow. These characteristics can favour adherence to treatment and therefore have a favourable effect on its clinical efficacy. Furthermore, it is the only itraconazole compatible with antacids.

The same posology as conventional Itraconazole

Itragerm 50 mg capsules are for oral administration and can be taken with or without food. One hard capsule of Itragerm 50 mg is equivalent to one hard capsule of conventional Itraconazole 100 mg. Therefore, the recommended dose of Itragerm is half the recommended dose of conventional Itraconazole hard capsules. The posology of Itragerm in adults for each indication is as follows:

Superficial mycosis (of the skin, mucous membranes, eyes)

The bioavailability of itraconazole can be reduced in some immunodepressed patients, e.g. with neutropenia, AIDS or transplants. Double the dose could be indicated.

Systemic mycoses

Duration of treatment will depend on clinical efficacy. uses cookies to guarantee the best experience for the user. If you continue browsing, we consider did you agree to their use. For more information see our COOKIES POLICY